Post navigation Intensity Therapeutics Regains Compliance with Nasdaq’s Minimum Bid Price RequirementAisa Pharma Announces Encouraging Results from Phase 2 RECONNOITER Trial of AISA-021 (Cilnidipine) in Patients with Systemic Sclerosis-Associated Raynaud’s Phenomenon